To mark World Health Day we spoke with Ivo Abraham from the University of Arizona (AZ, USA) about the role that biosimilars play in expanding access to cancer treatments, particularly in regards to the biosimilar filgrastim-sndz.
Browsing: Taxonomy > Drug development
This World Health Day the WHO is calling for robust steps towards universal healthcare with actions on a policy and an individual level. Find out about some of the issues in global health from across our sister sites.
In this interview find out what advancements have been made in the field of biosimilars and how they are helping improve access to cancer medicines.
Larotrectinib becomes the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.
Phase III IM power150 study has demonstrated that atezolizumab and bevacizumab plus carboplatin and paclitaxel helped individuals with advanced lung cancer live longer compared to avastin plus carboplatin and paclitaxel.
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate.
Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
A new drug, termed ixazomib, is to be used in combination with standard treatments and has been made available on the Cancer Drug Fund.
To mark World Cancer Day we are highlighting the most significant advancements in modern oncology to investigate how the field has advanced and what hurdles still need to be overcome.